枣庄癫痫诊断依据是什么聊城有什么偏方可以治癫痫,全国哪里有专治癫痫病的医院,东营治好癫痫要花多少钱,滨州癫痫病的治疗花费,山东权威的治疗痫病的医院,安徽儿童癫痫病医院哪家治疗效果好,泰安治羊癫疯病价格是多少

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

CANBERRA, Oct. 15 (Xinhua) -- Prisoners and health experts on Saturday told national broadcasting network ABC News that they are concerned of a looming HIV epidemic in Australia's prisons.The warning came following a test report undertaken in August showed that 40 percent of inmates at a correctional center in Canberra of Australia tested positive to Hepatitis C.According to the head of the Alcohol and Drug Service based at St Vincent's Hospital in Sydney, Alex Wodak, roughly 25 percent of Australia's prison population are injecting drugs, and he is concerned about the risk of an HIV explosion in Australia originating in prisons."Were Australia to have an epidemic of HIV beginning among people who inject drugs, it is almost certain that it would begin in one of our prisons. So we are very exposed to this risk," he told ABC News on Saturday.The Australia Capital Territory state government has proposed a trial prison needle exchange program in Canberra's correctional center, and Paul Cubitt, who currently works at the Alexander Maconochie Center in Canberra, said he has never seen so many syringes in a jail."Under a controlled regime it will actually take those needles that currently exist within a correctional center out of the environment, and prisoners will be more willing to use a clean item under a level of anonymity which then protects them and protects staff," he said.Meanwhile, The Community and Public Sector Union 's national secretary, Nadine Flood, agrees action must be taken to curb prisoner drug use.Dr Wodak noted that prison needle exchange programs have been operating overseas for over a decade with ten countries provide inmates with clean needles, and said it is shameful Australian prisons are lagging behind.

WASHINGTON, Sept. 30 (Xinhua) -- At least 15 people have been killed amid 84 sickened in 19 states in listeria outbreak traced to Colorado cantaloupes, making it the most deadly U.S. outbreak of food-borne infection since 1998, the Centers for Disease Control and Prevention (CDC) said Friday.Of the 15 victims, five were in New Mexico, three in Colorado, two in Texas, and one each in Kansas, Maryland, Missouri, Nebraska and Oklahoma. Health departments in Wyoming and Kansas have said they are investigating additional deaths that may be connected to the outbreak.The previous toll announced on Tuesday was 13 dead and 72 sick.The Food and Drug Administration on Sept. 14 warned consumers not to eat cantaloupes from Colorado's Rocky Ford region shipped by Jensen Farms. The cantaloupes with the brand name Rocky Ford were distributed from July 29 to Sept. 10 in at least 17 states."Even if some of the cantaloupe has been eaten without becoming ill, dispose of the rest of the cantaloupe immediately. Listeria bacteria can grow in the cantaloupe at room and refrigerator temperatures," the CDC said.Listeria is a common bacterium that typically causes mild illness in healthy people, but can cause severe illness in older people and those with compromised immune systems. It also can cause miscarriages and stillbirths in pregnant women and severe infections in new babies.Listeria infections lead to about 1,600 serious illnesses each year and about 260 people die, according to the CDC.The CDC estimates that about 48 million people in the U.S. each year get sick from tainted food, with about 128,000 hospitalized and 3,000 deaths.

SHENYANG, Nov. 17 (Xinhua) -- A MD-90 aircraft left the northeastern city of Shenyang for its American home on Thursday, ending the service of the last McDonnell-Douglas jet for Chinese airlines.Chinese carriers will no longer operate MD-made jets due to growing market demands, said Lu Changchun, deputy general manager with the north China branch of China Southern Airlines, which has operated the MD-90 jet for over a decade.MD-90 jets were involved in no accidents during the decade-long-service in China, so safety concerns did not lead to their retirement, Lu said, adding about 1,000 MD-90 jets are still flying around the world.Lu, however, admitted that supply of aircraft materials was affected as the production line of MD jets shrank, after McDonnell-Douglas Cooperation was merged into Boeing in 1997.MD jets were replaced mainly because Chinese airlines need new models to accommodate air travel demands fueled by the economic boom, Lu said.The north China branch of China Southern Airlines also announced Thursday the retirement of five A300-600R planes, which are replaced by A320 family jets. China Southern Airlines began flying an Airbus A380 superjumbo in China in October.China's domestic air travel market is predicted to grow 13.9 percent annually by 2014 and transport 379 million domestic air passengers, which will make the country the world's second-largest air travel market after the United States, according to a report released by the International Air Transport Association.Back in the 1990s, a Shanghai-based aircraft maker assembled two MD-90 jets in China, Lu said, adding the two jets retired this year.Change of jets model serves the strategic transformation of China Southern Airlines and meets the market demands, Lu said.Li Jiaxiang, chief of China's civil aviation administration, estimated that over 1.5 trillion yuan (235 billion U.S. dollars) will be invested in the civil aviation industry by 2015, adding about 2,000 aircraft to the country's fleet.Commercial Aircraft Corporation of China, producer of China's first self-developed jumbo jet, the C919, has announced that it will complete the design for the passenger plane in 2012. The jet is expected to take off in 2014 and put into service in 2016.

BEIJING, Dec. 10 (Xinhua) -- Pharmaceutical producers will risk having their operation license revoked if they use prohibited chemicals as medicine ingredients or involved in fake drug production, China's drug regulator said in a circular Saturday.The State Food and Drug Administration said it would name and shame pharmaceutical companies if they make phoney medicine and withdraw the operation licenses of pharmacies if they intentionally sell unqualified drugs.The circular came in the wake of several counterfeit medicine scandals uncovered by Chinese police in the past few months.On Nov. 4, police seized more than 65 million imitation medicinal tablets and arrested 114 suspects in a cross-provincial raid on counterfeit drugs.In October, police raided on an illegal drug production and sale network and ended up with the seizure of 190 million yuan (29.9 million U.S. dollars) worth of counterfeit drugs.The suspects were found to have used starch or corn powder as ingredients for bogus medicine, or re-packaged expired pharmaceuticals.Police also found animal feed and chemical pigments in the counterfeit products.